CONTROLLED TRIAL OF 1α-Hydroxycholecalciferol IN CHRONIC RENAL FAILURE

Tougaard, L.; Sørensen, Egon; Brøchner‐Mortensen, Jens; Christensen, Michael; Rødbro, P.; Sørensen, ArneW.S

doi:10.1016/s0140-6736(76)92220-0

Cited by 94 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hazardous values of the calcium-phosphorus product may thus be reached and this may accelerate the deterioration of renal function. Indeed, such an effect was regularly ob served when hypercalcemia was induced [5,18] but it has been observed even in patients with normal sCa levels [15]. All this renders the use of vitamin D3 metabolites inad visable for chronic uremics on conservative therapy.…”

Section: Discussionmentioning

confidence: 99%

Reversal of Hyperparathyroidism in Severe Uremics Following Very Low-Protein and Low-Phosphorus Diet

Barsotti¹,

Morelli²,

Guiducci³

et al. 1982

Nephron

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Reversal of Hyperparathyroidism in Severe Uremics Following Very Low-Protein and Low-Phosphorus Diet

Barsotti¹,

Morelli²,

Guiducci³

et al. 1982

Nephron

View full text Add to dashboard Cite

show abstract

“…Several studies have reported accelerated renal fail ure with the use of la-OHD.i or l.25(OH)aD3 which was greater than the decrease in renal function seen in untreated or in vitamin D-treated control patients [10,11]; but in these instances the deleterious effects could have been at tributable to hypercalcaemia. None of our own patients with accelerated renal failure were hypercalcaemic, but it is interesting that I of our patients (No.…”

Section: Discussionmentioning

confidence: 94%

Effects of Vitamin D Metabolites and Analogues on Renal Function

Naik

Cundy

Robinson

et al. 1981

Nephron

View full text Add to dashboard Cite

The long-term effects of vitamin D analogues and metabolites on renal function were assessed in 24 patients with and without chronic renal failure. Treatment for periods of 5–45 months did not adversely affect renal function in 10 of 11 patients with stable renal function, although transient hypercalcaemia did cause transient rises in plasma creatinine. Of 13 patients with progressive renal failure before treatment, vitamin D-like compounds or the vehicle used for their administration may have accelerated renal failure in 3 patients independently of changes in plasma calcium or phosphate. Particular difficulties in assessing the effects of vitamin D-like compounds in progressive renal disease are discussed.

show abstract

“…Since this improvement of renal osteodystrophy was achieved without acceleration of renal failure, these studies are quite interesting. One should, however, remember that 1.25(OH)2D3 does not only correct malabsorption of calcium but also that of phosphate [7] and that in patients with more advanced renal failure such treatment may lead to marked hyper phosphatemia which when combined with hypercal cemia accelerates the decline of renal function, as pre viously reported [8,9]. Furthermore, such an increase in plasma phosphate limits the beneficial effect of l,25(OH)2D3 on bone resorption [10], Finally, one should keep in mind that in experimental uremia la-OH vitamin D 3 given at doses keeping plasma calcium an phosphate in the normal range may increase the calcium content of the aorta [11] and that in man la-OH vitamin D3 increases plasma aluminum in uremic patients taking Al(OH)3 [12], Therefore, we ask ourself whether another approach for the prevention of hyperparthyroidism in early, as well as more advanced renal failure, would not simply be the use of oral calcium carbonate at the highest doses not inducing hypercalcemia greater than 10.4 mg/dl.…”

mentioning

confidence: 92%